Antimicrobial susceptibility pattern of carbapenemase-producing Gram-negative nosocomial bacteria at Al Zahra hospital, Isfahan, Iran

Sima Bahrami1, Fatemeh Shafiee2, Atousa Hakamifard3, Hossein Fazeli4, Rasool Soltani5*

1Students Research Committee, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
2Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
3Department of Infectious Diseases, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
4Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
5Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Received: August 2020, Accepted: November 2020

ABSTRACT

Background and Objectives: Bacterial antibiotic resistance is one of the most important threats for public health around the world. Carbapenemase-producing Gram-negative bacteria have resistance to most antibiotics including carbapenems complicating the treatment of infections. The aim of this study was to determine the antimicrobial susceptibility pattern of carbapenemase-producing nosocomial Gram-negative pathogens at a referral teaching hospital to reveal the best options for treatment of related infections.

Materials and Methods: Gram-negative bacteria, isolated from hospitalized patients with nosocomial infections, underwent meropenem susceptibility test by disk diffusion method. Meropenem-resistant strains were evaluated for the presence of carbapenemase using Modified Hodge test (MHT). Finally, the antibiotic susceptibility test was performed to determine the sensitivity of each carbapenemase-positive strain against various antimicrobial agents according to the guidelines of Clinical and Laboratory Standards Institute (CLSI).

Results: Over the study period, 155 carbapenemase-positive isolates were detected. Pneumonia was the most frequent related nosocomial infection (67.1%) followed by UTI (23.2%). Acinetobacter baumannii (53.5%) and Klebsiella pneumoniae (40%) were the most frequently isolated pathogens. The pathogens had high rate of resistance to all antibiotics. Colistin had the most in vitro effect against all pathogens. Also, K. pneumoniae had a co-trimoxazole sensitivity rate equal to colistin (30.6%).

Conclusion: Carbapenemase-positive Gram-negative bacteria causing nosocomial infections are common in our hospital and have high rate of resistance to most antibiotics. Improvement in the pattern of antibiotic use and infection control measures are necessary to overcome this resistance.

Keywords: Nosocomial infections; Carbapenemase; Antibiotic; Susceptibility
INTRODUCTION

Nosocomial infections occur during hospital care for other illnesses or even after the patient is discharged (1). Nosocomial infections lead to increased duration of hospital stay, physical disability, antibiotic resistance, socioeconomic disturbances, and finally, increased mortality (2). According to the Center for Disease Control and Prevention (CDC), nearly 1.7 million hospitalized patients annually acquire health care-associated infections (HCAIs) while being treated for other disorders and more than 98,000 of these patients (one in 17) die because of these infections (3). Generally, the prevalence of this type of infections is 3-20 times higher in low-income countries compared to the high-income ones (4). So, it is important to provide proper guidelines for the effective prevention of these infections. On the other hand, given the high prevalence of antibiotic resistance, choosing the right treatment for this type of infection is another challenge (5).

Bacterial antibiotic resistance is one of the most important threats of public health around the world based on the opinion of World Health Organization, and this needs to be addressed (6). The Centers for Disease Control and Prevention (CDC) estimates the additional cost of health care related to microbial resistance as 20 billion dollars (6).

Carbapenems are important therapeutic antibiotics against Gram-negative pathogens causing nosocomial infections (7). However, carbapenemase-producing strains develop resistance against these bacterial agents (8).

In recent years, there has been a significant increase in infections caused by multidrug-resistant bacteria in Gram-negative bacteria, especially carbapenemase-positive pathogens, worldwide (9-11). In a European survey, endemic spread of carbapenemase-producing Enterobacteriaceae was reported in 13 of 38 European countries in 2015, compared with 6 of 38 in 2013 (12). Furthermore, a higher spread was reported for Acinetobacter baumannii, with 12 of 27 European countries having more than 50% carbapenem resistance among the isolates (12). The vital problem is that carbapenemase-producing bacteria show resistance to other antibiotics, including fluoroquinolones and aminoglycosides, in addition to beta-lactam agents (8).

Given the growing trend of microbial resistance among carbapenemase-producing Gram-negative bacteria, which has led to limited treatment options as well as the irrational prescribing of antibacterial agents, the aim of the present study was to investigate the prevalence of Gram-negative carbapenemase-producing bacteria and their antibiotic resistance patterns at a referral teaching hospital to guide better selection of antimicrobial drugs for the treatment of these infections.

MATERIALS AND METHODS

Patients and setting. This was a prospective cross-sectional study performed at Al-Zahra hospital affiliated to Isfahan University of Medical Sciences (IUMS), Isfahan, Iran from January to June 2019.

The inclusion criteria for eligible patients were: 1) age ≥ 18 years; 2) hospitalization for at least 48 hours; 3) having clinical signs and symptoms of any infection with initiation after at least 48 hours of hospitalization; and 4) Growth of Gram-negative pathogen from the sample culture. Biological samples, including tracheal secretions, sputum, urine, wound secretions, cerebrospinal fluid, and blood were collected from the patients with signs and symptoms of related infections in various clinical wards of the hospital.

After transferring to the microbiology department of the hospital laboratory, the samples were cultured and grown microorganisms underwent differential tests in order to diagnose various bacterial species. Gram-negative pathogens were included in the study and the patients’ information including demographic data, hospitalization ward, the biological sample, the type of infection and its causative pathogen were recorded.

Carbapenem susceptibility test. The yielded Gram-negative pathogens were screened for carbapenem resistance using disk diffusion (Kirby-Bauer) method according to the Clinical and Laboratory Standards Institute (CLSI) instructions (13). Briefly, microbial suspension with 0.5 McFarland standard turbidity was cultured on Mueller-Hinton agar (Hi-Media, India) with meropenem disk (10 μg, Padtan Teh, Iran) being placed on it. The plates were incubated for 24 hours at 37°C. Following incubation, if the inhibition zone diameter around the meropenem disk showed resistance according to CLSI breakpoints (13), the pathogen underwent the test of carbapenemase presence at the next step.
 Modified Hodge test. To determine the presence of carbapenemase in each bacterial sample, modified Hodge test was used (14). Accordingly, 0.5 McFarland of microbial suspension containing E. coli (ATCC 25922), as a standard microorganism, was cultured on the surface of Mueller-Hinton agar with 1/10 dilution rate and allowed to dry for 3-5 minutes. After placing a meropenem disk (10 μg) in the middle of the plate, each microbial sample was drawn by a sterile swap as a straight line to the edge of the plate. For each sample, the test was repeated for Klebsiella pneumoniae (ATCC 1705) (containing carbapenemase enzyme) and the Klebsiella pneumoniae (ATCC 1706) without carbapenemase, as the positive and negative controls, respectively. After incubation for 24 hours at 37°C, the formation of a clover-like growth inhibition zone around the line confirmed the presence of carbapenemase in each microbial sample, while a negative MHT indicated no production of carbapenemase by the isolate. The quality control of meropenem disk was performed according to CLSI guidelines (13).

Antibiotic susceptibility test. Carbapenemase-positive bacterial isolates underwent antibiotic susceptibility test by disk diffusion method. After the inoculation of Mueller-Hinton agar with 0.5-McFarland microbial suspension, antibiotic disks including cepafepine (30 μg), ceftazidime (30 μg), ceftriaxone (30 μg), ampicillin (10 μg), piperacillin/tazobactam (100/10 μg), ampicillin/sulbactam (10/10 μg), trimethoprim-sulfamethoxazole (co-trimoxazole, 1.25/23.75 μg), gentamycin (10 μg), amikacin (30 μg), tetracycline (30 μg), azithromycin (15 μg), ciprofloxacin (5 μg), levofloxacin (5 μg), and colistin (10 μg) were placed on the surface at a distance of not less than 24 mm (center to center). After 24 hours of incubation at 37°C, the non-growth halo diameter around each disk was determined and recorded with the results being reported as susceptible (S), intermediate resistant (I), or resistant (R) according to the CLSI breakpoints (13). Due to the lack of zone diameter breakpoints for colistin against A. baumannii and Enterobacteriaceae, the following values were used based on a previous study (15): (i) A. baumannii: R ≥ 12, 12 < I < 14, and S ≥ 14 mm; (ii) Enterobacteriaceae: R ≤ 11, 11 < I < 14, and S ≥ 14 mm.

RESULTS

Over the study period, 300 patients were diagnosed with nosocomial infection that 261 of cases (87%) were recognized as Gram-negative infections including 168 and 93 cases in males and females, respectively. Furthermore, pneumonia was recorded as the most frequent infection (n = 172, 65.9%), followed by urinary tract infection (UTI; n = 61, 23.3%), central nervous system (CNS) infections (n = 15, 5.7%), wound infection (n = 9, 3.4%), and bacteremia (n = 4, 1.5%).

Regarding the frequency of the causative Gram-negative pathogens, A. baumannii (n = 130, 49.8%) and K. pneumoniae (n = 107, 41%) were the most frequently isolated microorganisms followed by P. aeruginosa (n = 23, 8.8%) and E. coli (n = 1, 0.38%).

Regarding the results of Hodge test, 155 cases (59.4%) was positive for carbapenemase with A. baumannii being the most frequent pathogen (n = 83, 53.5%) followed by K. pneumoniae (n = 62, 40%), P. aeruginosa (n = 9, 5.8%), and E. coli (n = 1, 0.7%). In addition, Pneumonia was the most frequent nosocomial infection due to these pathogens (n = 104, 67.1%; 57.7% in males), followed by UTI (n = 36, 23.2%; 50% in each gender), CNS infection (n = 11, 7.1%; 63.6% in males), and wound infection (n = 4, 2.6%; 50% in each gender). Table 1 shows the frequency of various carbapenemase-positive pathogens for each nosocomial infection. As shown, carbapenemase-positive A. baumannii and K. pneumoniae were the most frequent cause of pneumonia and UTI, respectively, while they had similar frequencies in CNS and wound infections.

Table 2 shows the antibiotic susceptibility of isolated carbapenemase-positive pathogens. As seen, there was high resistance rate amongst the isolated microorganisms to the tested antibiotics. Furthermore, colistin had the most in vitro effect against all pathogens. Also, K. pneumoniae had a co-trimoxazole sensitivity rate equal to colistin (30.6%).

Table 3 represents the antibiotic susceptibility of detected carbapenemase-positive nosocomial infections. As shown, pneumonia, CNS infections, and wound infections had the most susceptibility to colistin, while UTI had the most sensitivity to colistin (36%) and co-trimoxazole (26%).

DISCUSSION

In the present study, the prevalence of Gram-negative carbapenemase-producing bacteria and their
antibiotic resistance patterns at a referral university hospital was determined. Our results showed that 59.4% of isolated Gram-negative organisms were carbapenemase-positive. Furthermore, *A. baumannii* and *K. pneumoniae* were responsible for about 50% and 40% of detected hospital infections with 64% and 58% of the isolates being carbapenemase-positive, respectively. Various rates of carbapenemase resistance have been reported in the studies. In Zhang et al study in China, among 664 cases with resistance to carbapenems, 73.9% of infections were caused by *K. pneumoniae*, and 16.6% by *E. coli* (16). Howev-

---

**Table 1.** The frequency of carbapenemase-positive Gram-negative pathogens for each detected nosocomial infection.

| Pathogen     | n (%)          | Infection n (%)          | Pneumonia | UTI | CNS infection | Wound infection |
|--------------|----------------|--------------------------|-----------|-----|---------------|-----------------|
| *A. baumannii* | 83 (53.5)      | 67 (64.4)                | 9 (25)    | 5 (45.45) | 2 (50)        |
| *K. pneumoniae* | 62 (40)        | 33 (31.7)                | 22 (61.1) | 5 (45.45) | 2 (50)        |
| *P. aeruginosa* | 9 (5.8)        | 3 (2.9)                  | 5 (13.9)  | 1 (9.9)   | 0             |
| *E. coli*     | 1 (0.7)        | 1 (1)                    | 0         | 0         | 0             |
| Total        | 155            | 104                      | 36        | 11        | 4             |

**Table 2.** Antibiotic susceptibility of isolated carbapenemase-positive Gram-negative pathogens

| Pathogen               | Antibiotic       | n   | Susceptibility n (%) |
|------------------------|------------------|-----|----------------------|
| *Acinetobacter baumannii* | Ceftazidime      | 83  | Sensitive 0 Intermediate 0 Resistant 83 (100) |
|                        | Cefepime         | 83  | 0 (3.7)              | 78 (96.3) |
|                        | Ampicillin/sulbactam | 83 | 5 (6.2) 2 (2.5)     | 78 (91.3) |
|                        | Levofloxacin     | 83  | 1 (1.3)              | 80 (98.7) |
|                        | Amikacin         | 83  | 5 (6.2) 1 (1.2)     | 75 (92.6) |
|                        | Co-trimoxazole   | 83  | 3 (3.7)              | 78 (96.3) |
|                        | Colistin         | 83  | 25 (30.9)            | 56 (69.1) |
| *Klebsiella pneumoniae* | Ceftazidime      | 62  | 1 (1.6) 1 (1.6)     | 60 (96.8) |
|                        | Cefepime         | 62  | 0                  | 62 (100) |
|                        | Piperacillin/tazobactam | 62 | 1 (1.6) 0          | 61 (98.4) |
|                        | Ciprofloxacin    | 62  | 2 (3.3)              | 60 (96.7) |
|                        | Amikacin         | 62  | 7 (11.3) 1 (1.7)    | 54 (87)   |
|                        | Co-trimoxazole   | 62  | 19 (30.6)            | 41 (66.1) |
|                        | Colistin         | 62  | 19 (30.6)            | 43 (69.4) |
| *Pseudomonas aeruginosa* | Ceftazidime      | 9   | 2 (22.2)             | 7 (77.8)  |
|                        | Cefepime         | 9   | 2 (22.2)             | 7 (77.8)  |
|                        | Piperacillin/tazobactam | 9 | 1 (21.2) 0        | 8 (88.8)  |
|                        | Ciprofloxacin    | 9   | 1 (11.1)             | 7 (77.8)  |
|                        | Amikacin         | 9   | 2 (22.2)             | 7 (77.8)  |
|                        | Co-trimoxazole   | 9   | 0                   | 9 (100)   |
|                        | Colistin         | 9   | 5 (55.6)             | 4 (44.4)  |
| *Escherichia coli*     | Ceftazidime      | 1   | 0                   | 1 (100)   |
|                        | Cefepime         | 1   | 0                   | 1 (100)   |
|                        | Piperacillin/tazobactam | 1 | 1 (100) 0        | 0         |
|                        | Ciprofloxacin    | 1   | 1 (100)              | 0         |
|                        | Amikacin         | 1   | 1 (100)              | 0         |
|                        | Co-trimoxazole   | 1   | 0                   | 1 (100)   |
|                        | Colistin         | 1   | 0                   | 1 (100)   |
er, A. baumannii was not included in the evaluated pathogens. In another study performed in Uganda, the prevalence of carbapenemase-resistant Enterobacteriaceae was 22.4% (44/196) among the isolated pathogens and K. pneumoniae had the most frequency (52.2%) (17). In another study conducted in South Africa, it was shown that 68% of investigated microorganisms contained a carbapenemase-producing gene with 71% of the isolates being Klebsiella species (18). Similarly, in these two later studies, A. baumannii was not evaluated. Furthermore, in contrast to our work, the source of the isolates was not limited to the nosocomial ones. The results of Amjad et al. study in Pakistan were somewhat similar to our results as 138 out of 200 Gram-negative isolates (69%) were positive for carbapenemase in Modified Hodge test; however, the frequency of pathogens was very different so that E. coli (38%), and P. aeruginosa (30%) were the most frequent carbapenemase-positive bacteria followed by K. pneumoniae (17%), A. baumannii (12%), Citrobacter diversus (2%) and Enterobacter agglomerans (1.4%) (14). The differences in the type of evaluated microorganisms (Enterobacteriaceae vs. all Gram-negative pathogens), the region, and the source of the isolates (hospital-acquired vs. community-acquired) are responsible for these various results.

Our results showed that the most prevalent carbapenemase-positive hospital infections were pneumonia caused mostly by A. baumannii and UTIs mostly due to K. pneumoniae. Consistently, in a cohort study published in 2012, among 21 patients with UTIs, in 20 cases, the causative pathogen was K. pneumoniae with positive Hodge test (19). In the study of Gheitani

Table 3. Antibiotic susceptibility of detected carbapenemase-positive nosocomial infections.

| Antibiotic         | Susceptibility | Infection n (%)       |
|--------------------|----------------|-----------------------|
|                    |                | Pneumonia | UTI   | CNS infection | Wound infection |
| Ceftazidime        | S              | 1 (1)      | 1 (2.9) | 1 (10)      | 0                |
|                    | I              | 0          | 1 (2.9) | 0           | 0                |
|                    | R              | 100 (99)   | 33 (94.2) | 9 (90)      | 2 (100)          |
| Ceftepime          | S              | 1 (0.9)    | 1 (3)   | 0           | 0                |
|                    | I              | 3 (2.7)    | 0       | 0           | 0                |
|                    | R              | 108 (96.4) | 35 (97) | 10 (100)    | 2 (100)          |
| Piperacillin/tazobactam | S        | 0         | 1 (3.6) | 0           | 1 (100)          |
|                    | I              | 0         | 0       | 0           | 0                |
|                    | R              | 39 (100)  | 27 (96.4) | 5 (100)    | 0                |
| Ampicillin/sulbactam | S             | 6 (9.5)   | 0       | 0           | 0                |
|                    | I              | 1 (1.6)    | 0       | 1 (20)      | 0                |
|                    | R              | 56 (88.9) | 8 (100) | 4 (80)      | 1 (100)          |
| Ciprofloxacin      | S              | 0         | 2 (7.4) | 0           | 1 (100)          |
|                    | I              | 0         | 1 (3.7) | 0           | 0                |
|                    | R              | 35 (100)  | 24 (88.9) | 5 (100)    | 0                |
| Levofloxacin       | S              | 0         | 0       | 0           | 0                |
|                    | I              | 0         | 0       | 0           | 0                |
|                    | R              | 65 (100)  | 9 (100) | 5 (100)    | 1 (100)          |
| Amikacin           | S              | 9 (8.8)   | 4 (11.1) | 2 (20)      | 0                |
|                    | I              | 0         | 1 (2.8) | 0           | 1 (50)           |
|                    | R              | 93 (91.2) | 31 (86.1) | 8 (80)    | 1 (50)           |
| Co-trimoxazole     | S              | 12 (12.1) | 8 (25.8) | 1 (11.1)   | 0                |
|                    | I              | 1 (1)     | 1 (3.2) | 0           | 0                |
|                    | R              | 86 (86.9) | 22 (71) | 8 (88.9)   | 2 (100)          |
| Colistin           | S              | 23 (22.5) | 13 (36.1) | 3 (27.3)   | 2 (50)           |
|                    | I              | 0         | 0       | 0           | 0                |
|                    | R              | 79 (77.5) | 23 (63.9) | 8 (72.7)   | 2 (50)           |
and Fazeli on carbapenem-resistant _K. pneumoniae_, UTI was the most frequent infection (52.5%) caused by this pathogen (20). Therefore, it seems that carbapenem-resistant _K. pneumoniae_ is a major cause of nosocomial UTIs and this should be considered in the empiric treatment of this type of infections. Furthermore, resistant strains of _A. baumannii_ have become increasingly common cause of nosocomial infections globally since 1980 (21, 22). The most frequent clinical manifestations of _A. baumannii_ infection are pneumonia, as observed in our study, and BSIs (23) _A. baumannii_ was among the most common pathogens causing nosocomial pneumonia in a prospective observational study from 27 ICUs in nine European countries (23).

According to our results, carbapenem-resistant CNS infections were caused equally by _A. baumannii_ and _K. pneumoniae_. Gram-negative bacilli are common etiology of nosocomial meningitis, often occurring as a complication of head trauma and craniotomy (24). In a study performed in Turkey, among Gram-negative pathogens, _A. baumannii_ was the most frequently isolated pathogen (59.8%) from post-operative meningitis followed by _P. aeruginosa_ (13.4%) and _K. pneumoniae_ (12.2%) (25). Therefore, it seems that the type of causing pathogen is different between the centers.

Another aspect in our study was determining the susceptibility of isolated carbapenem-positive Gram-negative pathogens to various antibacterial agents. Our results showed that colistin was the most effective antibiotic against all isolated pathogens. However, yet a high rate of resistance was seen against this antibiotic (about 70% for _A. baumannii_ and _K. pneumoniae_ and 44% for _P. aeruginosa_). Different rates of colistin-resistance among _A. baumannii_ strains have been reported in several reports, mainly as a result of increased use of this agent for MDR isolates (26-28); In the study of Azimi et al. on carbapenem-resistant _A. baumannii_ isolated from burn patients in Tehran, only 55% strains with resistance to all investigated antibiotics were susceptible to colistin (29). Therefore, considering that colistin has been used as a first-line agent for the treatment of infections caused by carbapenem-resistant Gram-negative pathogens, implementing the strategies for saving this antibiotic is necessary. Furthermore, based on our results, none of other evaluated antibiotics was effective against _A. baumannii_. Similarly, in the study of Parandani et al. all of 19 isolates of carbapenem-producing _A. baumannii_ were resistant to cefepime, ceftazidime, and levofloxacin and only 14% were sensitive to tobramycin; however, in contrast to our results, all isolates (100%) were susceptible to colistin (30). Generally, it seems that carbapenem-producing strains of _A. baumannii_ convert to XDR (extensively drug resistant) strains with resistance to most antibiotics used for the treatment of infections due to this pathogen (29).

In the present study, co-trimoxazole had a sensitivity rate similar to colistin (30.6%) against _K. pneumoniae_. However, we did not find any other report of co-trimoxazole sensitivity among these strains. Therefore, this agent could be an option for treatment of carbapenem-producing _K. pneumoniae_ if susceptibility testing confirms its effectiveness. Of note, in contrast to our results, the sensitivity of carbapenem-resistant _A. baumannii_ to co-trimoxazole, determined by microbroth dilution method, has been shown in the study of Nepka et al. (31). The difference could be due to various methods of susceptibility testing as we used disk diffusion method. However, the low susceptibility rates in several other studies, as reported in the review of Falagas et al. (32), are consistent with our result. Nevertheless, as polymyxin-resistant _A. baumannii_ might still be susceptible to co-trimoxazole, the use of this agent should be carefully considered if it is still active.

One study showed that the most effective antibiotic groups for KPC-producing _K. pneumoniae_ are polymyxins and aminoglycosides (33), while 87% of amikacin (aminoglycoside) resistance was observed in our study. This difference could be due to the fact that we included the pathogens with all carbapenemase types, not only KPC type. Of note, according to other reports, KPC-positive isolates of _K. pneumoniae_ are commonly resistant to many antibiotics such as colistin (34, 35).

Overall, according to our results, colistin, co-trimoxazole, and an aminoglycoside (e.g., amikacin) could be considered for treatment of carbapenem-producing nosocomial Gram-negative pathogens in our hospital based on the results of antibiotic susceptibility testing. Although tygocycline could also be an option in this regard (36), we did not apply this agent in our investigation because of its unavailability in Iran.

The main limitation of this study was use of disk diffusion method for susceptibility testing of colistin in spite of CLSI statement recommending only broth
microdilution method for polymyxin susceptibility testing (13), as the poor agar diffusion characteristics of polymyxins limit the predictive accuracy of the disk diffusion test. However, broth microdilution is impractical for most clinical microbiology laboratories.

CONCLUSION

Carbenapenemase-producing Gram-negative bacteria causing nosocomial infections are common in our hospital and have high rate of resistance to most antibiotics. Acinetobacter baumannii and Klebsiella pneumoniae are the most common pathogens with the most sensitivity to colistin. Improvement in the pattern of antibiotic use and infection control measures are necessary to overcome this resistance.

REFERENCES

1. Khan HA, Baig FK, Mehoob R. Nosocomial infections: Epidemiology, prevention, control and surveillance. Asian Pac J Trop Biomed 2017; 7: 478-482.
2. Rajabi M, Abdar ME, Rafiei H, Aflatoonia MR, Abdar ZE. Nosocomial infections and epidemiology of antibiotic resistance in teaching hospitals in south east of Iran. Glob J Health Sci 2015; 8: 190-197.
3. Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007; 122: 160-166.
4. Haque M, Sartelli M, McKimm J, Abu Bakar M. Health care-associated infections – an overview. Infect Drug Resist 2018; 11: 2321-2333.
5. Heydarpour F, Rahmani Y, Heydarpour B, Asadamobi n A. Nosocomial infections and antibiotic resistance pattern in open-heart surgery patients at Imam Ali Hospital in Kermanshah, Iran. GMS Hyg Infect Control 2017; 12:Doc07.
6. Van Duin D, Doi Y. The global epidemiology of carbenapenemase-producing Enterobacteriaceae. Virulence 2017; 8: 460-469.
7. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 2012; 18: 263-272.
8. Castanheira M, Gales AC, Mendes RE, Jones R, Sader HS. Antibacterial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program. Clin Microbiol Infect 2004; 10: 645-651.
9. Kazmierczak KM, Biedenbach DJ, Hackel M, Rabine S, de Jonge BL, Bouchillon SK, et al. Global dissemination of blaKPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother 2016; 60: 4490-4500.
10. Lee C-R, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. Front Microbiol 2016; 7:895.
11. Spyropoulou A, Papadimitriou-Olivergeris M, Bartzaval i C, Vamvakopoulou S, Marangos M, Spiliopoulou I, et al. A ten-year surveillance study of carbapenemase-producing Klebsiella pneumoniae in a tertiary care Greek university hospital: predominance of KPC-over VIM-or NDM-producing isolates. J Med Microbiol 2016; 65: 240-246.
12. Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL, European Survey of Carbapenem-Producing Enterobacteriaceae (EuSCAPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill 2015; 20:30062.
13. Clinical and Laboratory Standards Institute (CLSI) performance standards for antimicrobial susceptibility testing. M100-S28, 2018, Wayne, PA.
14. Anjadj A, Mirza IA, Abbasi S, Farwa U, Malik N, Zia F. Modified Hodge test: A simple and effective test for detection of carbapenemase production. Iran J Microbiol 2011; 3: 189-193.
15. Galani I, Kontopodou F, Souli M, Rekatsina PD, Koratzanis E, Deliolas J, et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Agents 2008; 31: 434-439.
16. Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae infections: report from the China CRE Network. Antimicrob Agents Chemother 2018; 62(2):e01882-17.
17. Okoche D, Asimwe BB, Katabazi FA, Kato L, Najjuka CF. Prevalence and characterization of carbapenem-resistant Enterobacteriaceae isolated from Mulago National Referral Hospital, Uganda. PLoS One 2015; 10(8):e0135745.
18. Singh-Moodley A, Perovic O. Antimicrobial susceptibility testing in predicting the presence of carbapenemase genes in Enterobacteriaceae in South Africa. BMC Infect Dis 2016; 16: 536.
19. Alexander BT, Marschall J, Tibbetts RJ, Neuner EA, Dunne Jr WM, Ritchie DJ. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther 2012; 34: 1314-1323.
20. Gheitiani L, Fazeli H. Prevalence of bla VIM, bla IMP, and bla KPC genes among carbapenem-resistant *Klebsiella pneumoniae* (CRKP) isolated from Kurdistan and Isfahan hospitals, Iran. *Res Mol Med (RMM)* 2018; 6: 12-20.

21. Gaynes R, Edwards JR. National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram-negative bacilli. *Clin Infect Dis* 2005; 41: 848-854.

22. Tatman-Ötkun M, Gürcan S, Ozer B, Shokrylanbaran N. Annual trends in antibiotic resistance of nosocomial *Acinetobacter baumannii* strains and the effect of synergistic antibiotic combinations. *New Microbiol* 2004; 27: 21-28.

23. Munoz-Price LS, Weinstein RA. *Acinetobacter* infection. *N Engl J Med* 2008; 358: 1271-1281.

24. Wolff MA, Young CL, Ramphal R. Antibiotic therapy for enterobacter meningitis: a retrospective review of 13 episodes and review of the literature. *Clin Infect Dis* 1993; 16: 772-777.

25. Kurtaran B, Kuscu F, Ulu A, Inal AS, Komur S, Kibar F, et al. The causes of postoperative meningitis: the comparison of Gram-negative and gram-positive pathogens. *Turk Neurosurg* 2018; 28: 589-596.

26. Lesho E, Yoon EJ, McGann P, Snexrud E, Kwak Y, Milillo M, et al. Emergence of colistin-resistance in extremely drug-resistant *Acinetobacter baumannii* containing a novel pmcAB operon during colistin therapy of wound infections. *J Infect Dis* 2013; 208: 1142-1151.

27. Lopez-Rojas R, McConnell MJ, Jimenez-Mejias ME, DominguezHerrera J, Fernandez-Cuena F, Pachon J. Colistin resistance in a clinical *Acinetobacter baumannii* strain appearing after colistin treatment: effect on virulence and bacterial fitness. *Antimicrob Agents Chemother* 2013; 57: 4587-4589.

28. Pelletier MR, Casella LG, Jones JW, Adams MD, Zawaski DV, Hazlett KR, et al. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2013; 57: 4831-4840.

29. Azimi L, Talebi M, Pourshafie M-R, Owlia P, Lari AR. Characterization of carbapenemases in extensively drug resistant *Acinetobacter baumannii* in a burn care center in Iran. *Int J Mol Cell Med* 2015; 4: 46-53.

30. Paranandi A, Maloney M, Grogan E, Macierowski B, Noel D, Razeq J, et al. 548. Carbapenem-resistant *Acinetobacter baumannii* antibiotic susceptibility testing and antibiogram formation, connecticut 2017–2019. *Open Forum Infect Dis* 2019; (6Suppl 2): S261.

31. Nepka M, Perivolioti E, Kraniotaki E, Politis L, Tsakris A, Pournaras S. *In vitro* bactericidal activity of trimethoprim-sulfamethoxazole alone and in combination with colistin against carbapenem-resistant *Acinetobacter baumannii* clinical isolates. *Antimicrob Agents Chemother* 2016; 60: 6903-6906.

32. Falagas ME, Vardakas KZ, Roussos NS. Trimethoprim/sulfamethoxazole for *Acinetobacter* spp: a review of current microbiological and clinical evidence. *Int J Antimicrob Agents* 2015; 46: 231-241.

33. Campos AC, Albiero J, Ecker AB, Kuroda CM, Meirelles LE, Polato A, et al. Outbreak of *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: A systematic review. *Am J Infect Control* 2016; 44: 1374-1380.

34. Battikh H, Harchay C, Dekhili A, Khazar K, Kechrid F, Zribi M, et al. Clonal spread of colistin-resistant *Klebsiella pneumoniae* coproducing KPC and VIM carbapenemases in neonates at a Tunisian university hospital. *Microb Drug Resist* 2017; 23: 468-472.

35. Woodford N, Zhang J, Warner M, Kaufmann ME, Matos J, Macdonald A, et al. Arrival of *Klebsiella pneumoniae* producing KPC carbapenemase in the United Kingdom. *J Antimicrob Chemother* 2008; 62: 1261-1264.

36. Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. *Clin Infect Dis* 2019; 69(Suppl 7):S565-S575.